Univ of California @ Los Angeles (Site 325)
Welcome,         Profile    Billing    Logout  
 5 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Nghiemphu, Phioanh
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Calendar Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
POPLAR-NF2, NCT05130866: Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

Recruiting
2/3
92
US
REC-2282, AR-42, OSU-HDAC42, NSC-D736012, Placebo
Recursion Pharmaceuticals Inc.
Neurofibromatosis Type 2
01/27
07/27
NCT01149850: Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma

Completed
2
50
US
bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, anti-VEGF rhuMAb, Avastin, recombinant humanized anti-VEGF monoclonal antibody, rhuMAb VEGF, temozolomide, CCRG-81045, M & B 39831, SCH 52365, Temodal, Temodar, TMZ, laboratory biomarker analysis, immunohistochemistry staining method, immunohistochemistry, microarray analysis, gene expression profiling, DNA methylation analysis
Jonsson Comprehensive Cancer Center, Genentech, Inc.
Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma
12/23
12/23
INTUITT-NF2, NCT04374305: Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis

Active, not recruiting
2
100
US
Brigatinib, Alunbrig, Neratinib, Nerlynx
Scott R. Plotkin, MD, PhD, Takeda, The Children's Tumor Foundation, National Comprehensive Cancer Network
Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma, Ependymoma
12/29
12/30

Download Options